All In Biotech

Drug Trial Radar · NCT00208299

ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)

A Phase III, Randomized, Double-Blind Study of Intravenous CVT-3146 Versus Adenoscan® in Patients Undergoing Stress Myocardial Perfusion Imaging

Last checked: Nov 20, 2026Latest source record: Nov 26, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,231 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,231

Actual

Start

Oct 2003

Primary completion

Aug 2006

Study completion Aug 2006

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
Collaborators
Astellas Pharma US, Inc.
First posted
Sep 21, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Adenoscan® (adenosine) is an approved pharmacological stress agent indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. The investigational drug, regadenoson (CVT-3146) is a selective A2A adenosine receptor agonist, the receptor responsible for coronary vasodilation, and is being studied for potential use as a pharmacologic stress agent in myocardial perfusion imaging (MPI) studies. This study will compare the safety and efficacy of regadenoson to that of Adenoscan in detecting reversible myocardial perfusion defects.

Conditions

  • Coronary Artery Disease

Interventions

  • RegadenosonDrug

    0.4 mg, bolus intravenous injection

  • AdenosineDrug

    0.14 mg/kg/min for 6 minutes, intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Non-inferiority of regadenoson to Adenoscan for use in single photon emission computed tomography (SPECT) myocardial perfusion imaging in assessing reversible perfusion defectsTime frame: After radiopharmaceutical administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Multiple study locations (see Central Contact); CV Therapeutics, Inc.

    Palo Alto, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.